In 2022, MIRV received accelerated approval by US FDA for the treatment of adult patients with FRα-positive, platinum-resistant epithelial ovarian cancer (PROC), fallopian tube cancer or primary peritoneal cancer, previously treated with 1-3 prior systemic anti-cancer regimens (11). This evidence concerns the gene FOLR1 and fallopian tube cancer.